The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ae Hydrocarbon pneumonitis

I. Interstitial/parenchymal lung disease

I.af Chemical (toxic) pneumonitis

I. Interstitial/parenchymal lung disease

I.ag Fire-eater's lung/pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.k Bronchiectasis

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.d Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.s Sniffing death - Death from inhalation of compound

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XV. Pathology

XV.as Path: Fire eater's lung

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ah Imaging: Pneumatoceles (see also XVIaf)

XVI. Imaging

XVI.cb Imaging: Pneumatocele or pneumatoceles

XVII. Infections & related conditions

XVII.p Lung abscess/abscesses (see also VIr)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

VI. Pulmonary vasculopathy

VI.e Fat/oil embolism - The FES embolism syndrome

XV. Pathology

XV.ae Path: Lipid/fat embolism (see also VIe)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.s A mass or masses

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ap Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.w Plugs/casts in the airways

VII. Mediastinal involvement

VII.o Lipid-laden mediastinal lymphadenopathy

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XIII. Neoplastic conditions

XIII.a Lung cancer

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.q Path: Foreign body deposits/granulomatous reaction

XV. Pathology

XV.dd Path: Exogenous lipid-laden lymphadenopathy

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.r Imaging: An area or areas of involvement with low attenuation numbers

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.z Imaging: A large nodule or a mass

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.az Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bc Imaging: Intrathoracic lymph node enlargement

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.r Eye catcher: A milky, cloudy or lumpy BAL fluid

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.j BAL: Free exogenous lipids in supernatant

XXIV. Veterinary medicine

XXIV.f Veterinary: Exogenous lipoid pneumonia

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.ap Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.d Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages